Stifel raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $66 from $60 and keeps a Buy rating on the shares. The firm continues to have conviction that XTOLE-2 will be a positive study that derisks a $2B-plus opportunity for XEN1101, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals Issues Inducement Stock Options to New Hires
- Xenon Pharmaceuticals: Undervalued ‘Pipeline-in-a-Drug’ Story with Blockbuster Potential Ahead of Key 2026 Readouts
- Xenon Pharmaceuticals: Advancing Late-Stage Epilepsy and Depression Programs and Expanding NaV1.7/Kv7 Pipeline Support Buy Rating and $55 Target
- Xenon Sets 2026–2027 Milestone Timetable for Azetukalner and Pain Pipeline
- Xenon Pharmaceuticals outlines key upcoming milestones